Erasca Quarterly Income Statement
NASDAQ: ERASHealth CareBiotechnology: Pharmaceutical PreparationsUSD
16.03+0.57 (+3.69%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Erasca revenue and earnings
Erasca reported a net loss of $44.1 million, compared with a loss of $33.9 million a year earlier. Diluted earnings per share came in at -$0.14.
Summary generated from market data by MetaCap's automated system. Methodology
Erasca income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 47.62M | 187.91M | 32.60M | 34.55M | 38.13M | 35.63M | 35.71M | 37.24M | 67.78M | 38.85M | 33.87M | 34.66M |
| Research & Development | 35.90M | 27.27M | 23.24M | 22.47M | 21.17M | 25.97M | 26.12M | 27.63M | 33.03M | 28.57M | 24.80M | 25.21M |
| Operating Income | -47.62M | -187.91M | -32.60M | -34.55M | -38.13M | -35.63M | -35.71M | -37.24M | -67.78M | -38.85M | -33.87M | -34.66M |
| Other Income (Expense) | 3.54M | 4.47M | 3.51M | 3.93M | 4.25M | 4.66M | 3.48M | 6.04M | 4.58M | 3.83M | 4.17M | 4.30M |
| Net Income | -44.08M | -183.44M | -29.09M | -30.61M | -33.88M | -30.97M | -32.23M | -31.20M | -63.20M | -35.02M | -29.70M | -30.36M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.14 | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 | -0.06 | -0.11 | -0.29 | -0.23 | -0.20 | -0.20 |
| EPS (Diluted) | -0.14 | -0.60 | -0.10 | -0.11 | -0.12 | -0.11 | -0.06 | -0.11 | -0.29 | -0.23 | -0.20 | -0.20 |
| Shares Outstanding (Basic) | 311.34M | 304.32M | — | 283.68M | 283.36M | 283.26M | — | 282.38M | 217.81M | 151.16M | — | 150.45M |
| Shares Outstanding (Diluted) | 311.34M | 304.32M | — | 283.68M | 283.36M | 283.26M | — | 282.38M | 217.81M | 151.16M | — | 150.45M |
| EBITDA | -46.90M | -187.19M | -31.86M | -33.79M | -37.34M | -34.81M | -34.88M | -36.40M | -66.68M | -37.85M | -32.93M | -33.72M |
This table shows 12 quarterly periods of Erasca's income statement, from Q2 2026 back to Q3 2023, across 10 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow ERAS's reporting calendar. What is a income statement?